Management of patients with hepatitis C virus resistance-associated variants to NS5A inhibitors: Where are we now?

Clinical Liver Disease

Volumn 6, Issue 4, 2015, Pages 82-85

  Wells, Jennifer T ^a   Landaverde, Carmen ^a   Gutierrez, Julio ^a   Lawitz, Eric ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR PLUS BECLABUVIR PLUS DACLATASVIR; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; ELBASVIR; GRAZOPREVIR; LEDIPASVIR PLUS SOFOSBUVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5A INHIBITOR; NONSTRUCTURAL PROTEIN 5B; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL THERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1A; HEPATITIS C VIRUS GENOTYPE 1B; HEPATITIS C VIRUS GENOTYPE 7; HUMAN; LIVER CIRRHOSIS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

EID: 84945271911     PISSN: None     EISSN: 20462484     Source Type: Journal    
DOI: 10.1002/cld.507     Document Type: Review

References (16)

1. McGovern BH, Abu Dayyeh BK, Chung RT. Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection. Hepatology 2008;48:1700-1712.
2. Blight KJ, Kolyhalov AA, Reed KE, Agapov EV, Rice CM. Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets. Antiviral Ther 1998;3:71-81.
3. Tomei L, Failla C, Santolini E, De Francesco R, La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 1993;67:4017-4026.
4. Lindenbach B, Rice CM. Unraveling hepatitis C virus replication from genome to function. Nature 2005;436:933-938.
5. Kieffer TL. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010;65:202-212.
6. Kwong AD, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, et al. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG. Gastroenterology 2011;140:7557-7560.
7. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010;2:30ra32.
8. Ralston R, Vierling J, Lawitz E, McCone J, Gordon S, Pound D, et al. Long-term follow-up of patients treated with boceprevir in combination with PEG-intron/ribavirin (P/R): durability of responses and rates of reversion of resistance mutations. Available at: http://www.natap.org/2010/ResisWksp/ResisWksp_25.htm. Accessed May 20, 2015.
9. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138:447-462.
10. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle B, Martin R, Zeuzem S, et al. The prevalence and the effect of HCV NS5A resistance-associated variants in patients with compensated cirrhosis treated with ledipasvir/sofosbuvir ± RBV. Presented at the European Association for the Study of the Liver 50th International Liver Congress. Vienna, Austria. April 22-26, 2015.
11. Reddy KR, Beavers KL, Gordon S, Harrison S, Reau N, Yozviak J, de Ledinghen V, et al. Effect of baseline factors on response to the fixed-dose combination of daclatasvir, asunaprevir and beclabuvir in non-cirrhotic patients with HCV genotype 1 infection. Presented at the European Association for the Study of the Liver 50th International Liver Congress. Vienna, Austria. April 22-26, 2015.
12. Black S, Pak I, Ingravallo P, McMonagle P, Chase R, Shaughnessy M, et al. Resistance analysis of virologic failures in hepatitis C genotype 1-infected patients treated with grazoprevir + elbasvir ± ribavirin: the C-WORTHY study Presented at the European Association for the Study of the Liver 50th International Liver Congress. Vienna, Austria. April 22-26, 2015.
13. Wyles D, Mangia A, Cheng W, Shafran S, Schwabe C, Ouyang W. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. Presented at the European Association for the Study of the Liver 50th International Liver Congress. Vienna, Austria. April 22-26, 2015.
14. Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Dekhtyar T, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens. Presented at the European Association for the Study of the Liver 50th International Liver Congress. Vienna, Austria. April 22-26, 2015.
15. Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015;313:1728-1735.
16. Lawitz E, Flamm S, Yang JC, Phillip S, Pang PS, Zhu Y, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. Presented at the European Association for the Study of the Liver 50th International Liver Congress. Vienna, Austria. April 22-26, 2015.